U.S., March 24 -- ClinicalTrials.gov registry received information related to the study (NCT07487103) titled 'Efficacy and Safety of QLG1090 vs Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes' on March 17.
Brief Summary: This study is to evaluate the efficacy and safety of QLG1091 vs Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes. The primary objective is to demonstrate equivalence of QLG1091 and Rybelsus. This study is a randomized, double-blind, double-dummy, active-controlled, parallel-group, multi-center Study. The total duration of the study will be approximately 33 weeks including screening and follow-up.
Study Start Date: April 01
Study Type: INTERVENTIONAL
Condition:
Type 2 Diabetes
Intervent...